Results 71 to 80 of about 25,335 (131)
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Oropharyngeal Adverse Events to Drugs and Vaccines: Pharmacovigilance Data From Italy (2019–2021)
Oral Diseases, Volume 31, Issue 3, Page 993-1005, March 2025.ABSTRACT Objectives The aim of this study was to perform a descriptive analysis of oropharyngeal adverse events (AEs) related to drugs and/or vaccines in order to provide useful information for clinicians. Methods Data related to three regions of Italy were analyzed from 2019 to 2021 by using the National Pharmacovigilance database.
Liberata Sportiello +16 more
wiley +1 more source
Blau Syndrome (Juvenile Systemic Granulomatosis): State‐Of‐The‐Art Review
Pediatric Dermatology, EarlyView.ABSTRACT Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain‐of‐function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated.
Ou Jia (Emilie) Wang +3 more
wiley +1 more source
Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases
Periodontology 2000, EarlyView.Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva +2 more
wiley +1 more source
Arthritis &Rheumatology, Volume 77, Issue 6, Page 765-776, June 2025.Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal +5 more
wiley +1 more source
Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis [PDF]
, 2018 Objective: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor alpha. We report mavrilimumab long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107 ...
Achuthan +44 more
core +1 more source
Clinical Case Reports, Volume 13, Issue 6, June 2025.ABSTRACT Autoimmune disorders occur when the body's immune system mistakenly attacks its own tissues. Generally, these disorders are more prevalent in female patients. The presence of one autoimmune disease can alter the immune system's balance, making the individual more susceptible to developing other autoimmune conditions.
Suaad Hamsho +2 more
wiley +1 more source
Experience with the use of Rituximab for the treatment of rheumatoid arthritis in a tertiary Hospital in Spain: RITAR study [PDF]
, 2019 There is evidence supporting that there are no relevant clinical differences between dosing rituximab 1000 mg or 2000 mg per cycle in rheumatoid arthritis (RA) patients in clinical trials, and low-dose cycles seem to have a better safety profile ...
Alvaro García, José M. +11 more
core +2 more sources
Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis [PDF]
, 2015 ObjectivesTo estimate the cost-effectiveness of tocilizumab (TCZ) monotherapy (Mono) versus adalimumab (ADA) Mono from the US payer perspective in patients with rheumatoid arthritis for whom methotrexate is inappropriate.MethodsWe compared TCZ Mono (8 mg/
Carlson, Josh J. +3 more
core +1 more source